Telomere Science Library

Publications, Presentations, and Videos
about the Nobel-Prize Winning Science of Telomere Biology

Successful treatment with rituximab and mycophenolate mofetil of refractory autoimmune hemolytic anemia post-hematopoietic stem cell transplant for dyskeratosis congenita due to TINF2 mutation.

Authors: Niall N. O'Connell, Matthew M. Goodyer, Mary M. Gleeson, Lorna L. Storey, Martina M. Williams, Melanie M. Cotter, Aengus A. O'Marcaigh, Owen O. Smith
Published: 10/29/2013, Pediatric transplantation


AIHA following allogeneic HSCT is appearing more frequently in the literature. It occurs as a result of donor cell-derived antibodies targeting donor red cell antigens. Little guidance exists on the management of such patients, particularly in the pediatric setting. First-line conventional treatment is corticosteroids and/or immunoglobulin therapy with monoclonal antibody therapy reserved for treatment failure. We report our experience of a child refractory to immunoglobulin and steroid therapy who required several infusions of rituximab and immunomodulatory therapy to obtain a clinically significant response.

© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
PubMed Full Text